Haemonetics (HAE) Shares Outstanding (Weighted Average) (2009 - 2026)

Haemonetics' Shares Outstanding (Weighted Average) history runs 18 years deep, the most recent figure standing at $47.2 million for Q1 2026.

• In Q1 2026, Shares Outstanding (Weighted Average) fell 6.26% year-over-year to $47.2 million; the TTM figure through Mar 2026 stood at $47.2 million (down 6.26% YoY), while the FY2026 annual figure was $47.2 million, down 6.26% from the prior year.
• Shares Outstanding (Weighted Average) was $47.2 million for Q1 2026 at Haemonetics, down from $47.5 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $51.2 million in Q3 2022 to a low of $47.2 million in Q1 2026.
• Historically, Shares Outstanding (Weighted Average) has averaged $50.1 million across 5 years, with a median of $50.7 million in 2023.
• The sharpest annual moves came in 2024 and 2026: Shares Outstanding (Weighted Average) advanced 0.79% in 2024, then fell 6.26% in 2026.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $50.9 million in 2022, then dropped by 0.43% to $50.7 million in 2023, then fell by 0.78% to $50.3 million in 2024, then fell by 5.55% to $47.5 million in 2025, then retreated by 0.67% to $47.2 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $47.2 million (Q1 2026), $47.5 million (Q4 2025), and $47.8 million (Q3 2025), per Business Quant data.